RSV

CDC Panel Votes to Broaden RSV Vaccine Eligibility for Older Adults

3 days ago

In a significant development regarding public health, the advisory panel of the Centers for Disease Control and Prevention (CDC) has voted in favor of expanding the eligibility for respiratory syncytial virus (RSV) vaccinations among older adults. This decision aims to enhance protection against respiratory illnesses that disproportionately affect the senior population, particularly during the peak of the RSV season.

Cellnex Plans to Repurchase Up to $800 Million in Shares in 2025

3 months ago

Cellnex, the prominent Spanish telecommunications infrastructure giant, has announced its intention to buy back as much as $800 million worth of its own shares in 2025. This strategic move is seen as a significant effort to enhance shareholder value amid evolving market conditions and rising demand for telecom infrastructure.

New Advisory for GSK and Pfizer's RSV Vaccines Due to Rare Neurological Disorder Risks

3 months ago

In a newly released advisory, health authorities have notified clinicians and the public about a potential risk associated with the respiratory syncytial virus (RSV) vaccines developed by GSK and Pfizer. These vaccines, which have been hailed as significant advancements in the fight against RSV, are now under scrutiny due to reports revealing a rare neurological disorder potentially linked to their use.

GSK's RSV Vaccine Demonstrates Long-Lasting Protection Across Multiple Seasons

6 months ago

In a significant development for public health, GlaxoSmithKline (GSK) has announced that its respiratory syncytial virus (RSV) vaccine shows promising durability in its protective effects, extending its efficacy over a remarkable three seasons. This finding is pivotal as RSV poses a substantial risk, particularly for infants and elderly populations, leading to severe respiratory illnesses and hospitalizations each year.